Topic: nonalcoholic steatohepatitis (NASH)
Shire has quietly cut the trial of an FDA fast-tracked fatty liver disease drug, although it’s not giving much away about what happened.
HotSpot Therapeutics, a new drug discovery venture exploring protein regulation, has kicked off with $45 million in series A financing.
Gilead’s senior director of clinical research, Adrian Ray, has moved to Nimbus Therapeutics to become its senior vice president of discovery biology.
Gilead is eagerly awaiting phase 3 data for its rheumatoid arthritis drug filgotinib that could be an antidote for the biotech’s hepatitis C hangover.
Shares in Gemphire more than doubled after its lead drug gemcabene aced a trial in patients with high triglycerides, setting up a phase 3 test.
Akero Therapeutics raised $65 million to advance its lead program, a FGF21 analog, for the treatment of NASH.
Nodthera raised £28 million in series A funding to develop NLRP3 inflammasome inhibitors for chronic inflammation.
Galmed unveiled top-line results from a yearlong phase 2b study of its NASH treatment, showing reductions in liver fat without worsening fibrosis.
Metacrine raised $65 million to launch phase 1 testing of its FXR agonist in NASH and gastrointestinal diseases later this month.
Nimbus reined in $65 million in funding for its virtual drug discovery and expand into new targets in immunology, oncology and metabolic diseases.